Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.

The fireside chat will be available for on-demand viewing beginning January 10, at 7:00 a.m. ET via the Investors & Media section of Janux’s website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.

About Janux Therapeutics

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), and its lead TRACIr program targeting PD-L1xCD28, with all of its programs currently in the IND-enabling or discovery stage. For more information, please visit www.januxrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005799/en/

Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
[email protected]
(858) 344-8091

Investors:
Christina Tartaglia
Stern Investor Relations, Inc.
[email protected]
(212) 362-1200

Source: Janux Therapeutics, Inc.

You May Also Be Interested In

• Everstage Recognized as a Challenger in the 2026 Gartner® Magic Quadrant™ for Sales Performance Management
• Half-year Liquidity Contract Statement for VEOLIA ENVIRONNEMENT
• Class Valuation verified by Fannie Mae and Freddie Mac to support new Uniform Property Data Report specification